Changes in T lymphocyte subsets in mice with CT26 colon tumors after treatment with donor lymphocyte infusion

[1]  J. Sprent,et al.  CD70–CD27 ligation between neural stem cells and CD4+ T cells induces Fas–FasL-mediated T-cell death , 2013, Stem Cell Research & Therapy.

[2]  A. Nagler,et al.  Regulatory T Cells in Allogeneic Stem Cell Transplantation , 2013, Clinical & developmental immunology.

[3]  T. Nettelbeck,et al.  A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. , 2013, Cancer treatment reviews.

[4]  C. Gross,et al.  Toxicity of bevacizumab in combination with chemotherapy in older patients. , 2013, The oncologist.

[5]  Xin-en Huang,et al.  Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[6]  J. Melenhorst,et al.  Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant , 2013, Haematologica.

[7]  Z. Mo,et al.  XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis , 2013, Cancer Chemotherapy and Pharmacology.

[8]  F. Goldwasser,et al.  Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer , 2012, The Journal of Immunology.

[9]  A. Dickinson,et al.  Immune Reconstitution and Graft-Versus-Host Reactions in Rat Models of Allogeneic Hematopoietic Cell Transplantation , 2012, Front. Immun..

[10]  B. Yeap,et al.  Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras , 2012, PloS one.

[11]  Y. Jie,et al.  Specific immunosuppression by mixed chimerism with bone marrow transplantation after Staphylococcal Enterotoxin B pretreatment could prolong corneal allograft survival in mice , 2012, Molecular vision.

[12]  M. Abecassis,et al.  Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation , 2012, Science Translational Medicine.

[13]  A. Takeuchi,et al.  A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti‐tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice , 2012, International journal of cancer.

[14]  D. Porter.  Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. , 2011, Hematology. American Society of Hematology. Education Program.

[15]  I. Flinn,et al.  High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas , 2011, Leukemia & lymphoma.

[16]  D. Porter,et al.  Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies , 2010, Expert review of hematology.

[17]  R. Negrin,et al.  NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. , 2010, Blood.

[18]  Zhibin Chen,et al.  Immune Tolerance Induction by Integrating Innate and Adaptive Immune Regulators , 2010, Cell transplantation.

[19]  S. L. Petersen.  Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2007, Danish medical bulletin.

[20]  C. Marth,et al.  Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. , 1996, Blood.

[21]  S. Slavin,et al.  Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. , 1984, Journal of immunology.

[22]  A. Sarnaik,et al.  Immunotherapy for gastrointestinal malignancies. , 2013, Cancer control : journal of the Moffitt Cancer Center.

[23]  G. Dranoff,et al.  Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. , 2001, Cancer research.